Keywords: sanofi, pasteur-msd, cancer, drug, promises, strong, growth

Sanofi Pasteur-MSD cancer drug promises strong growth, the company says

Article | 22 December 2006

Sanofi Pasteur MSD's uterine cancer vaccine Gardasil (quadrivalent Human Papillomavirus [types 6, 11, 16, 18] recombinant vaccine) is expected to transform the position of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Aventis

Aventis Pharma

Sanofi-Aventis

Go to company listing

Related Drugs

Gardasil

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Quadrivalent Human Papillomavirus

Go to drug listing